phosphorylcholine has been researched along with sirolimus in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (12.50) | 18.2507 |
| 2000's | 9 (37.50) | 29.6817 |
| 2010's | 11 (45.83) | 24.3611 |
| 2020's | 1 (4.17) | 2.80 |
| Authors | Studies |
|---|---|
| Anderson, WH; Chung, T; Crilly, KS; Kiss, Z; Mukherjee, JJ | 1 |
| Crilly, KS; Kiss, Z; Tomono, M | 1 |
| Anderson, WH; Kiss, Z; Mukherjee, JJ | 1 |
| Carter, AJ; Collingwood, R; Gibson, L; Sedlik, S; Virmani, R | 1 |
| Kandzari, DE; Leon, MB | 1 |
| Bonan, R; Fajadet, J; Fitzgerald, PJ; Kuck, KH; Kuntz, RE; Laarman, GJ; Münzel, T; Ormiston, J; Popma, JJ; Wijns, W | 1 |
| Abizaid, A; Centemero, M; Chaves, A; Feres, F; Fitzgerald, PJ; Lansky, AJ; Mattos, L; Schwartz, LB; Sousa, AG; Sousa, JE; Staico, R; Tanajura, LF; Zaugg, MJ | 1 |
| Chen, W; Dong, W; Fan, D; Gao, R; Ji, J; Jia, Z; Liu, X; Qiu, H; Ren, K; Shen, J; Sun, F; Xu, J; Yan, X | 1 |
| Bonneau, HN; Cutlip, D; Fajadet, J; Fitzgerald, PJ; Honda, Y; Hongo, Y; Kuntz, RE; Popma, JJ; Sakurai, R; Wijns, W; Yamasaki, M; Yock, PG; Zimetbaum, P | 1 |
| Dannecker, R; Sayer, C; Schuler, W; Sedrani, R; Zollinger, M | 1 |
| Ako, J; Fitzgerald, PJ; Hasegawa, T; Honda, Y; Kandzari, DE; Leon, MB; Miyazawa, A; Sakurai, R; Tsujino, I; Waseda, K; Yock, PG | 1 |
| Hou, P; Liu, D; Liu, Z; Wu, G; Xing, M | 1 |
| Anderson, KC; Cirstea, D; Desai, N; Gorgun, G; Hideshima, T; Ikeda, H; Kapoor, S; Mukherjee, S; Munshi, NC; Patel, K; Perrone, G; Pozzi, S; Raje, N; Rodig, S; Santo, L; Sportelli, P; Vali, S; Vallet, S | 1 |
| Becher, OJ; Bradbury, MS; Charles, N; Chenevert, TL; Galbán, CJ; Galbán, S; Hambardzumyan, D; Holland, EC; Li, F; Pitter, KL; Rehemtulla, A; Ross, BD; Saeed-Tehrani, O; Tehrani, OS | 1 |
| Chinn, DC; Gandara, DR; Holland, WS; Lara, PN; Mack, PC; Pietri, JE; Tepper, CG | 1 |
| Baek, KJ; Jeong, HS; Kim, DS; Kwon, NS; Lee, SH; Park, KC; Yun, HY | 1 |
| Chaumeil, MM; Haas-Kogan, DA; James, CD; Ronen, SM; Venkatesh, HS; Ward, CS | 1 |
| Li, P; Luo, X; Ma, Z; Wang, X; Zhai, S; Zhu, L | 1 |
| Civallero, M; Cosenza, M; Marcheselli, L; Pozzi, S; Sacchi, S | 1 |
| Arora, R; Bahekar, A; Bajaj, A; Bhuriya, R; Khosla, S; Sethi, A; Singh, PP | 1 |
| Ho, SL; Lavi, E; Singh, R; Souweidane, MM; Zhou, Z | 1 |
| Chen, R; Hu, G; Hu, J; Liu, J; Liu, W; Ning, R; Wang, Y; Wu, L; Xiong, J; Yang, J | 1 |
| Ahn, J; Byun, JK; Choi, BG; Choi, CU; Choi, SY; Choi, WG; Her, AY; Jang, WY; Kang, DO; Kang, TS; Kim, W; Kim, YH; Lee, MH; Park, CG; Park, JY; Park, SH; Park, Y; Rha, SW; Seo, HS | 1 |
| Abrey, LE; DeAngelis, LM; Gavrilovic, I; Holland, EC; Kaley, TJ; Lacouture, ME; Lassman, AB; Ludwig, E; Mellinghoff, IK; Nolan, C; Omuro, A; Panageas, KS; Pentsova, EI | 1 |
2 review(s) available for phosphorylcholine and sirolimus
| Article | Year |
|---|---|
Overview of pharmacology and clinical trials program with the zotarolimus-eluting endeavor stent.
Topics: Anti-Inflammatory Agents; Blood Vessel Prosthesis Implantation; Clinical Trials as Topic; Coated Materials, Biocompatible; Combined Modality Therapy; Coronary Restenosis; Coronary Stenosis; Humans; Phosphorylcholine; Prosthesis Design; Sirolimus; Stents | 2006 |
Zotarolimus-eluting stent versus sirolimus-eluting and paclitaxel-eluting stents for percutaneous coronary intervention: a meta-analysis of randomized trials.
Topics: Coated Materials, Biocompatible; Confidence Intervals; Coronary Angiography; Coronary Restenosis; Drug-Eluting Stents; Equipment Failure; Follow-Up Studies; Humans; Myocardial Infarction; Paclitaxel; Percutaneous Coronary Intervention; Phosphorylcholine; Randomized Controlled Trials as Topic; Sirolimus; Thrombosis; Treatment Outcome | 2012 |
5 trial(s) available for phosphorylcholine and sirolimus
| Article | Year |
|---|---|
Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions. Clinical and angiographic results of the ENDEAVOR II Trial.
Topics: Aged; Australia; Cardiovascular Agents; Coronary Angiography; Coronary Restenosis; Coronary Stenosis; Double-Blind Method; Drug Delivery Systems; Equipment Design; Europe; Female; Humans; Israel; Male; Middle Aged; New Zealand; Pacific Islands; Phosphorylcholine; Prospective Studies; Sirolimus; Stents; Treatment Outcome | 2007 |
Percutaneous coronary revascularization using a trilayer metal phosphorylcholine-coated zotarolimus-eluting stent.
Topics: Aged; Angioplasty, Balloon, Coronary; Blood Vessel Prosthesis Implantation; Cardiovascular Agents; Coronary Angiography; Coronary Circulation; Coronary Restenosis; Coronary Stenosis; Female; Follow-Up Studies; Humans; Male; Middle Aged; Phosphorylcholine; Prospective Studies; Prosthesis Design; Research Design; Sirolimus; Stents; Treatment Outcome; Tunica Intima; Ultrasonography, Interventional | 2007 |
Detailed intravascular ultrasound analysis of Zotarolimus-eluting phosphorylcholine-coated cobalt-chromium alloy stent in de novo coronary lesions (results from the ENDEAVOR II trial).
Topics: Chromium Alloys; Coated Materials, Biocompatible; Cohort Studies; Coronary Artery Disease; Coronary Restenosis; Double-Blind Method; Endosonography; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Phosphorylcholine; Prospective Studies; Sirolimus; Stents; Tunica Intima | 2007 |
Intravascular ultrasound results from the ENDEAVOR IV trial: randomized comparison between zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease.
Topics: Aged; Alloys; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Coated Materials, Biocompatible; Cobalt; Coronary Artery Disease; Coronary Restenosis; Drug-Eluting Stents; Female; Humans; Hyperplasia; Male; Middle Aged; Paclitaxel; Phosphorylcholine; Prosthesis Design; Single-Blind Method; Sirolimus; Time Factors; Treatment Outcome; Tunica Intima; Ultrasonography, Interventional; United States | 2009 |
Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Drug Therapy, Combination; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Phosphorylcholine; Prospective Studies; Proto-Oncogene Proteins c-akt; Sirolimus; TOR Serine-Threonine Kinases; Young Adult | 2020 |
17 other study(ies) available for phosphorylcholine and sirolimus
| Article | Year |
|---|---|
ATP-dependent choline phosphate-induced mitogenesis in fibroblasts involves activation of pp70 S6 kinase and phosphatidylinositol 3'-kinase through an extracellular site. Synergistic mitogenic effects of choline phosphate and sphingosine 1-phosphate.
Topics: 3T3 Cells; Adenosine Triphosphate; Androstadienes; Animals; Calcium-Calmodulin-Dependent Protein Kinases; Cell Division; DNA; Drug Synergism; Enzyme Activation; Enzyme Inhibitors; Harvey murine sarcoma virus; Immunosuppressive Agents; Insulin; Kinetics; Lysophospholipids; Mice; Models, Biological; Phosphatidylinositol 3-Kinases; Phospholipases A; Phosphorylcholine; Phosphotransferases (Alcohol Group Acceptor); Polyenes; Protein Serine-Threonine Kinases; Recombinant Proteins; Ribosomal Protein S6 Kinases; Sirolimus; Sphingosine; Thymidine; Transfection; Wortmannin | 1997 |
Bombesin and zinc enhance the synergistic mitogenic effects of insulin and phosphocholine by a MAP kinase-dependent mechanism in Swiss 3T3 cells.
Topics: 3T3 Cells; Androstadienes; Animals; Bombesin; DNA Replication; Drug Synergism; Enzyme Activation; Immunoblotting; Insulin; Mice; Mitogen-Activated Protein Kinase 1; Mitogens; Phosphorylcholine; Polyenes; Sirolimus; Thymidine; Wortmannin; Zinc | 1997 |
Ethanol potentiates the stimulatory effects of insulin and phosphocholine on mitogenesis by a zinc-dependent and rapamycin-sensitive mechanism in fibroblasts and JB6 cells.
Topics: 3T3 Cells; Adenosine Triphosphate; Animals; Calcium-Calmodulin-Dependent Protein Kinases; Cell Division; Cysteine Proteinase Inhibitors; DNA Replication; Drug Synergism; Ethanol; Fibroblasts; Insulin; Mice; Mitosis; Phosphorylcholine; Polyenes; Sirolimus; Zinc | 1998 |
Stent-based delivery of ABT-578 via a phosphorylcholine surface coating reduces neointimal formation in the porcine coronary model.
Topics: Angioplasty, Balloon, Coronary; Animals; Coated Materials, Biocompatible; Coronary Vessels; Disease Models, Animal; Feasibility Studies; Graft Occlusion, Vascular; Immunosuppressive Agents; Phosphorylcholine; Sirolimus; Stents; Swine; Treatment Outcome; Tunica Intima | 2005 |
[Pilot study of a cell membrane like biomimetic drug-eluting coronary stent].
Topics: Angioplasty, Balloon, Coronary; Animals; Coated Materials, Biocompatible; Coronary Restenosis; Drug-Eluting Stents; Female; Humans; Male; Materials Testing; Methacrylates; Phosphorylcholine; Pilot Projects; Polymers; Prosthesis Design; Random Allocation; Sirolimus; Swine; Swine, Miniature | 2007 |
The macrolide everolimus forms an unusual metabolite in animals and humans: identification of a phosphocholine ester.
Topics: Animals; Chromatography, Liquid; Esters; Everolimus; Humans; Immunosuppressive Agents; Lymphocyte Culture Test, Mixed; Male; Mass Spectrometry; Phosphorylcholine; Rats; Rats, Wistar; Sirolimus | 2008 |
Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin.
Topics: Animals; Cell Growth Processes; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Humans; Mice; Mice, Nude; Oncogene Protein v-akt; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylcholine; Protein Kinases; RNA, Small Interfering; Signal Transduction; Sirolimus; Thyroid Neoplasms; TOR Serine-Threonine Kinases; Transfection; Xenograft Model Antitumor Assays | 2009 |
Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma.
Topics: Albumins; Animals; Apoptosis; Autophagy; Bone Marrow Cells; Caspases; Cell Line, Tumor; Cell Proliferation; Cell Survival; Down-Regulation; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Activation; Humans; Insulin-Like Growth Factor I; Interleukin-6; Intracellular Signaling Peptides and Proteins; Mice; Multiple Myeloma; Nanoparticles; Phosphorylation; Phosphorylcholine; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2010 |
Perifosine and CCI 779 co-operate to induce cell death and decrease proliferation in PTEN-intact and PTEN-deficient PDGF-driven murine glioblastoma.
Topics: Animals; Antineoplastic Agents; Cell Death; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Synergism; Glioblastoma; Mice; Phosphatidylinositol 3-Kinases; Phosphorylcholine; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Sirolimus | 2011 |
Evaluating rational non-cross-resistant combination therapy in advanced clear cell renal cell carcinoma: combined mTOR and AKT inhibitor therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Interleukin-8; Kidney Neoplasms; Neovascularization, Pathologic; Oligonucleotide Array Sequence Analysis; Phosphorylation; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Sirolimus; TOR Serine-Threonine Kinases | 2012 |
Involvement of mTOR signaling in sphingosylphosphorylcholine-induced hypopigmentation effects.
Topics: Analysis of Variance; Animals; Blotting, Western; Cell Line; Chromones; Dose-Response Relationship, Drug; Hypopigmentation; Luciferases; Melanins; Mice; Microscopy, Phase-Contrast; Monophenol Monooxygenase; Morpholines; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Signal Transduction; Sirolimus; Sphingosine; TOR Serine-Threonine Kinases; Transfection | 2011 |
Reduced phosphocholine and hyperpolarized lactate provide magnetic resonance biomarkers of PI3K/Akt/mTOR inhibition in glioblastoma.
Topics: Antineoplastic Agents; Biomarkers; Cell Line, Tumor; Chromones; Enzyme Inhibitors; Everolimus; Glioblastoma; Humans; Lactic Acid; Magnetic Resonance Spectroscopy; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylcholine; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2012 |
Perifosine enhances mTORC1-targeted cancer therapy by activation of GSK3β in NSCLC cells.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Female; Gene Knockdown Techniques; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Lung Neoplasms; Mechanistic Target of Rapamycin Complex 1; Mice; Mice, Nude; Molecular Targeted Therapy; Multiprotein Complexes; Phosphorylation; Phosphorylcholine; Proteins; RNA, Small Interfering; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2012 |
NVP-BEZ235 alone and in combination in mantle cell lymphoma: an effective therapeutic strategy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Bone Marrow; Cell Line, Tumor; Cell Proliferation; Everolimus; Flow Cytometry; G1 Phase Cell Cycle Checkpoints; Humans; Imidazoles; Indoles; Lymphoma, Mantle-Cell; Phosphorylation; Phosphorylcholine; Protein Kinases; Quinolines; Sirolimus | 2012 |
Toxicity evaluation of prolonged convection-enhanced delivery of small-molecule kinase inhibitors in naïve rat brainstem.
Topics: Animals; Antineoplastic Agents; Brain Stem; Convection; Dasatinib; Drug Delivery Systems; Everolimus; Female; Infusions, Intraventricular; Phosphorylcholine; Protein Kinase Inhibitors; Pyrimidines; Rats; Rats, Sprague-Dawley; Sirolimus; Thiazoles | 2015 |
Decreased carboxylesterases expression and hydrolytic activity in type 2 diabetic mice through Akt/mTOR/HIF-1α/Stra13 pathway.
Topics: Animals; Basic Helix-Loop-Helix Transcription Factors; Blood Glucose; Carboxylic Ester Hydrolases; Diabetes Mellitus, Type 2; Disease Models, Animal; Gene Knockdown Techniques; Glucose; Hep G2 Cells; Hepatocytes; Homeodomain Proteins; Humans; Hydrolysis; Hypoxia-Inducible Factor 1, alpha Subunit; Insulin; Intestines; Liver; Male; Mice, Inbred C57BL; Overweight; Phosphorylcholine; Proto-Oncogene Proteins c-akt; RNA, Messenger; RNA, Small Interfering; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2015 |
Three-year major clinical outcomes of phosphorylcholine polymer- vs biolinx polymer-zotarolimus-eluting stents: A propensity score matching study.
Topics: Aged; Cardiovascular Diseases; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Phosphorylcholine; Polymers; Propensity Score; Prosthesis Design; Reoperation; Sirolimus | 2019 |